1561 related articles for article (PubMed ID: 29956204)
1. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Farrell GC; Haczeyni F; Chitturi S
Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
[TBL] [Abstract][Full Text] [Related]
2. Decoding cell death signals in liver inflammation.
Brenner C; Galluzzi L; Kepp O; Kroemer G
J Hepatol; 2013 Sep; 59(3):583-94. PubMed ID: 23567086
[TBL] [Abstract][Full Text] [Related]
3. TLR9 is up-regulated in human and murine NASH: pivotal role in inflammatory recruitment and cell survival.
Mridha AR; Haczeyni F; Yeh MM; Haigh WG; Ioannou GN; Barn V; Ajamieh H; Adams L; Hamdorf JM; Teoh NC; Farrell GC
Clin Sci (Lond); 2017 Aug; 131(16):2145-2159. PubMed ID: 28687713
[TBL] [Abstract][Full Text] [Related]
4. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent.
Gan LT; Van Rooyen DM; Koina ME; McCuskey RS; Teoh NC; Farrell GC
J Hepatol; 2014 Dec; 61(6):1376-84. PubMed ID: 25064435
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
7. Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.
Lebeaupin C; Vallée D; Rousseau D; Patouraux S; Bonnafous S; Adam G; Luciano F; Luci C; Anty R; Iannelli A; Marchetti S; Kroemer G; Lacas-Gervais S; Tran A; Gual P; Bailly-Maitre B
Hepatology; 2018 Aug; 68(2):515-532. PubMed ID: 29457838
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis and non-alcoholic fatty liver diseases.
Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
[TBL] [Abstract][Full Text] [Related]
9. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
10. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
Larter CZ; Chitturi S; Heydet D; Farrell GC
J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
[TBL] [Abstract][Full Text] [Related]
11. Microvesicles released from fat-laden cells promote activation of hepatocellular NLRP3 inflammasome: A pro-inflammatory link between lipotoxicity and non-alcoholic steatohepatitis.
Cannito S; Morello E; Bocca C; Foglia B; Benetti E; Novo E; Chiazza F; Rogazzo M; Fantozzi R; Povero D; Sutti S; Bugianesi E; Feldstein AE; Albano E; Collino M; Parola M
PLoS One; 2017; 12(3):e0172575. PubMed ID: 28249038
[TBL] [Abstract][Full Text] [Related]
12. Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis.
Martínez L; Torres S; Baulies A; Alarcón-Vila C; Elena M; Fabriàs G; Casas J; Caballeria J; Fernandez-Checa JC; García-Ruiz C
Oncotarget; 2015 Dec; 6(39):41479-96. PubMed ID: 26539645
[TBL] [Abstract][Full Text] [Related]
13. Attenuated lipotoxicity and apoptosis is linked to exogenous and endogenous augmenter of liver regeneration by different pathways.
Weiss TS; Lupke M; Ibrahim S; Buechler C; Lorenz J; Ruemmele P; Hofmann U; Melter M; Dayoub R
PLoS One; 2017; 12(9):e0184282. PubMed ID: 28877220
[TBL] [Abstract][Full Text] [Related]
14. Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.
Hirsova P; Ibrahim SH; Krishnan A; Verma VK; Bronk SF; Werneburg NW; Charlton MR; Shah VH; Malhi H; Gores GJ
Gastroenterology; 2016 Apr; 150(4):956-67. PubMed ID: 26764184
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2.
Bathish B; Robertson H; Dillon JF; Dinkova-Kostova AT; Hayes JD
Free Radic Biol Med; 2022 Aug; 188():221-261. PubMed ID: 35728768
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of Nonalcoholic Steatohepatitis.
Machado MV; Diehl AM
Gastroenterology; 2016 Jun; 150(8):1769-77. PubMed ID: 26928243
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic Steatohepatitis.
Suzuki A; Diehl AM
Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells.
Csak T; Ganz M; Pespisa J; Kodys K; Dolganiuc A; Szabo G
Hepatology; 2011 Jul; 54(1):133-44. PubMed ID: 21488066
[TBL] [Abstract][Full Text] [Related]
20. Lipotoxicity and steatohepatitis in an overfed mouse model for non-alcoholic fatty liver disease.
Gaemers IC; Stallen JM; Kunne C; Wallner C; van Werven J; Nederveen A; Lamers WH
Biochim Biophys Acta; 2011 Apr; 1812(4):447-58. PubMed ID: 21216282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
